Skip to main content
. 2014 Sep 9;26(5):1195–1204. doi: 10.1681/ASN.2014010096

Figure 1.

Figure 1.

Contributors associated with mesangial C3 deposits in IgAN. (A) The rs6677604-A allele was associated with lower intensity of mesangial C3 deposits. Patients with IgAN with the AA/AG genotype of rs6677604 (n=95) had high intensity of mesangial C3 deposits compared with those with the rs6677604-GG genotype (n=1083) (0, 1+, 2+, and 3+–4+: 13.7%, 28.4%, 31.6%, and 26.3%, respectively, in rs6677604-AA/AG versus 10.1%, 16.4%, 39.2%, and 34.3%, respectively, in rs6677604-GG; P=0.01). (B) Lower circulating C3 levels were associated with greater mesangial C3 deposition. Circulating C3 levels decreased significantly from 0 to 3+–4+ mesangial C3 deposition in patients with IgAN (0, 1+, 2+, and 3+–4+: 1.09±0.26, 1.08±0.20, 1.03±0.23, and 0.96±0.21 g/L, respectively; P<0.001; n=106, n=169, n=382, and n=351, respectively). (C and D) Higher circulating IgA and Gd-IgA1 levels were associated with greater mesangial C3 deposition. From 0 to 3+–4+ mesangial C3 deposition, significantly increased levels of circulating IgA (0, 1+, 2+, and 3+–4+: 2.95±1.19, 3.08±1.22, 3.19±1.10, and 3.39±1.23 g/L, respectively; P=0.001; n=109, n=173, n=390, and n=357, respectively) and Gd-IgA1 levels (0, 1+, 2+, and 3+–4+: 279.61±144.68, 306.50±128.64, 313.29±128.89, and 350.15±165.54 units/ml, respectively; P<0.009; n=38, n=82, n=177, and n=183, respectively) were observed in patients with IgAN.